Prudential Financial Inc. grew its stake in shares of Halyard Health, Inc. (NYSE:HYH) by 9.3% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 660,629 shares of the medical instruments supplier’s stock after buying an additional 56,350 shares during the period. Prudential Financial Inc. owned approximately 1.41% of Halyard Health worth $25,949,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. BlackRock Inc. raised its position in shares of Halyard Health by 6,362.1% during the first quarter. BlackRock Inc. now owns 5,939,352 shares of the medical instruments supplier’s stock valued at $226,229,000 after buying an additional 5,847,442 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Halyard Health by 4.7% during the first quarter. Vanguard Group Inc. now owns 4,350,518 shares of the medical instruments supplier’s stock valued at $165,711,000 after buying an additional 196,367 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Halyard Health by 18.8% during the first quarter. Dimensional Fund Advisors LP now owns 2,625,156 shares of the medical instruments supplier’s stock valued at $99,992,000 after buying an additional 415,105 shares during the last quarter. State Street Corp raised its position in shares of Halyard Health by 1.8% during the first quarter. State Street Corp now owns 1,583,269 shares of the medical instruments supplier’s stock valued at $60,306,000 after buying an additional 28,718 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its position in Halyard Health by 0.4% in the second quarter. Bank of New York Mellon Corp now owns 885,238 shares of the medical instruments supplier’s stock worth $34,772,000 after purchasing an additional 3,596 shares in the last quarter. 91.02% of the stock is owned by institutional investors and hedge funds.

Shares of Halyard Health, Inc. (NYSE:HYH) opened at 45.30 on Monday. Halyard Health, Inc. has a 52 week low of $31.59 and a 52 week high of $45.49. The company has a market capitalization of $2.12 billion, a PE ratio of 43.56 and a beta of 1.76. The firm’s 50-day moving average is $41.86 and its 200 day moving average is $39.30.

Halyard Health (NYSE:HYH) last issued its earnings results on Wednesday, August 2nd. The medical instruments supplier reported $0.51 EPS for the quarter, beating the consensus estimate of $0.37 by $0.14. The company had revenue of $399.20 million during the quarter, compared to analysts’ expectations of $399.16 million. Halyard Health had a net margin of 3.06% and a return on equity of 8.29%. The business’s revenue for the quarter was down .2% compared to the same quarter last year. During the same period in the previous year, the company earned $0.45 EPS. On average, analysts anticipate that Halyard Health, Inc. will post $1.98 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Halyard Health, Inc. (HYH) Shares Bought by Prudential Financial Inc.” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another domain, it was copied illegally and republished in violation of international copyright & trademark laws. The correct version of this article can be read at https://www.thecerbatgem.com/2017/09/04/halyard-health-inc-hyh-shares-bought-by-prudential-financial-inc.html.

Several research firms recently issued reports on HYH. Stephens raised shares of Halyard Health from an “equal weight” rating to an “overweight” rating in a research report on Thursday, August 3rd. BidaskClub raised shares of Halyard Health from a “hold” rating to a “buy” rating in a research report on Saturday, August 19th. Deutsche Bank AG increased their price target on shares of Halyard Health from $35.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Zacks Investment Research raised shares of Halyard Health from a “hold” rating to a “buy” rating and set a $44.00 price target for the company in a research report on Wednesday, July 12th. Finally, TheStreet raised shares of Halyard Health from a “c” rating to a “b” rating in a research report on Thursday, June 22nd. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Halyard Health presently has a consensus rating of “Buy” and an average target price of $42.25.

About Halyard Health

Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.

Institutional Ownership by Quarter for Halyard Health (NYSE:HYH)

Receive News & Stock Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related stocks with our FREE daily email newsletter.